Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

Item
http://www.wikidata.org/entity/Q34355672
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersA robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.Protein-polymer conjugation-moving beyond PEGylation.Control of Hepatitis B Virus by CytokinesHalf-life extended biotherapeutics.Fine Tuning of a Type 1 Interferon Antagonist.The molecular basis for differential type I interferon signaling.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties.Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity.
P2860

Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

Item
http://www.wikidata.org/entity/Q34355672
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@ast
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@en
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@nl
type
label
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@ast
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@en
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@nl
prefLabel
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@ast
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@en
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Enhanced in vivo efficacy of a ...... se model of multiple sclerosis
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932